An early-stage CNS therapeutic company on whose board I sit is looking for investments in the UK or the United States. They describe their focus as “development of novel CNS assets that span from early development to human clinical trial stages.” If you would like to learn more, please let me know using the contact form.
An interesting thread on the topic of educational paths to enter the biotechnology industry has popped up in the Journal of Commercial Biotechnology Linkedin group. Are you intrigued? Do you have any guidance? Hop over and join the discussion.
Check out the Journal of Commercial Biotechnology and my Biotechnology Books for more information on the business of biotechnology.
The Turkish response to the innovation score I generated for them in the Scientific American Worldview Scorecard was pretty clear. They interpret their low score — 39th out of 48 countries measured — as an indication that they continue to ‘miss the biotech train.’ The primary reasons for Turkey’s low score are:
- Relatively weak intellectual property protection
- Relatively low intensity of biotechnology activities
- Relatively poor capital availability for biotechnology ventures
- Relatively weak educational output of scientists
- Relatively low R&D expenditures by domestic companies
The solution to improving Turkey’s standing seems pretty clear — strengthen IP, implement programs to encourage students to study science, and support investments in company formation and R&D. But, these are not simple changes. As India has seen in their dispute over Novartis’ Glivec patents, strengthening IP protection may mean balancing short-term domestic interests with the future potential of foreign investments. Promoting company formation and the development of scientists can also be challenging. My recent study of the locations of pharmaceutical drug inventors came to a surprising conclusion: the dominant countries are the legacy pharma countries. Despite their significant investments, emerging markets have yet to produce measurable outputs in innovation.
So, what is Turkey to do? I think that it is a bit harsh to say that they continue to miss the train. Many countries strive to develop biotechnology industries, and fail to show progress despite significant investments. Turkey is blessed with a strong entrepreneurial culture, and can get ‘on the train’ if they decide to provide patient sustained support. The key to developing a stronger biotechnology industry is to continue to find and clear hurdles to innovation. Case studies from around the world are in plentiful supply — the challenge is to identify and implement the solutions best suited to Turkey.
Drug Patent Expirations in July 2011
*Drugs may be covered by multiple patents
|Tradename||Applicant||Generic Name||Patent Number|| Patent Expiration|
|ALAMAST||Santen||pemirolast potassium||5,034,230*PED||Jul 2, 2011|
|ANZEMET||Sanofi Aventis Us||dolasetron mesylate||4,906,755||Jul 2, 2011|
|ISTODAX||Celgene||romidepsin||4,977,138||Jul 6, 2011|
|VISIPAQUE 320||Ge Healthcare||iodixanol||RE36418||Jul 12, 2011|
|VISIPAQUE 270||Ge Healthcare||iodixanol||RE36418||Jul 12, 2011|
|MESNEX||Baxter Hlthcare||mesna||5,262,169||Jul 16, 2011|
|MESNEX||Baxter Hlthcare||mesna||5,252,341||Jul 16, 2011|
|UROXATRAL||Sanofi Aventis Us||alfuzosin hydrochloride||4,661,491*PED||Jul 18, 2011|
|EQUETRO||Validus Pharms Inc||carbamazepine||5,326,570||Jul 23, 2011|
|CARBATROL||Shire||carbamazepine||5,326,570||Jul 23, 2011|
|RAPAMUNE||Wyeth Pharms Inc||sirolimus||5,145,684*PED||Jul 25, 2011|
|DENTIPATCH||Noven||lidocaine||5,332,576||Jul 26, 2011|
|MULTAQ||Sanofi Aventis Us||dronedarone hydrochloride||5,223,510||Jul 26, 2011|
This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin.
Courtesy of DrugPatentWatch.com